Epizyme Thursday priced its treatment for an uncommon, slow rising kind of cancer that impacts soft tissue at $15,500 per month after getting a license from the U.S. Food and Drug Administration.
Epithelioid sarcoma (ES) affects practically 800 individuals in the U.S. and usually begins in the soft tissue under the pores and skin of a finger, hand, forearm, lower leg, or foot.
The therapy, Tazverik, is accredited for patients aged 16 and above and comes after a board of specialists to the U.S. regulator voted consistently in favor of the drug’s support in December.
The company stated its commercial launch plans were underway, and expects to make Tazverik available throughout the U.S. inside 10 days.
The medicine was approved under the accelerated approval pathway and is contingent upon the results of a confirmatory trial.
Tazverik can also be currently being examined for other varieties of cancer, including follicular lymphoma, which is under evaluation by the FDA.
Epizyme has filed a marketing application for the drug’s use on people living with follicular lymphoma who’ve received a minimum of two prior lines of remedy.